Alpha 2.0
Login Register
» Authors » Christoph Mancao

Christoph Mancao

Explore the profile of Christoph Mancao including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 1266
Followers 0
Related Specialties
Oncology
Hematology
General Medicine
Top 10 Co-Authors
Heinz-Josef Lenz
Wu Zhang
Shivani Soni
Francesca Battaglin
Joshua Millstein
Hiroyuki Arai
Fotios Loupakis
Chiara Cremolini
Sebastian Stintzing
Alfredo Falcone
Published In
Blood
Clin Cancer Res
Eur J Cancer
Br J Cancer
J Thorac Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies
Cannarile M, Karanikas V, Reis B, Mancao C, Lagkadinou E, Ruttinger D, et al.
Clin Cancer Res . 2023 Dec; 30(8):1448-1456. PMID: 38100047
Despite the clinical validation and unequivocal benefit to patients, the development of cancer immunotherapies is facing some key challenges and the attrition rate in early phases of development remains high....
2.
Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials
Wang J, Millstein J, Yang Y, Stintzing S, Arai H, Battaglin F, et al.
EClinicalMedicine . 2023 Feb; 57:101827. PMID: 36816347
Background: Antiangiogenic drug (AAD)-triggered oxygen and nutrient depletion through suppression of angiogenesis switches glucose-dependent to lipid-dependent metabolism. Blocking fatty acid oxidation can enhance AAD-mediated anti-tumor effects in colorectal cancer (CRC)....
3.
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)
Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, et al.
Cancer Commun (Lond) . 2022 Nov; 42(12):1314-1330. PMID: 36336841
Background: Treatment options for Chinese patients with locally advanced or metastatic squamous-cell non-small-cell lung cancer (sqNSCLC) after failure of first-line chemotherapy are limited. This study (ORIENT-3) aimed to evaluate the...
4.
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials
Wang J, Xiao Y, Loupakis F, Stintzing S, Yang Y, Arai H, et al.
Eur J Cancer . 2022 Jun; 172:22-30. PMID: 35749909
Background: The activation of stimulator of interferon genes (STING) was reported to enhance cetuximab-mediated natural killer cell activation and dendritic cell maturation. Polymorphisms in genes in the cyclic GMP-AMP synthase...
5.
fdrci: FDR confidence interval selection and adjustment for large-scale hypothesis testing
Millstein J, Battaglin F, Arai H, Zhang W, Jayachandran P, Soni S, et al.
Bioinform Adv . 2022 Jun; 2(1):vbac047. PMID: 35747247
Motivation: Approaches that control error by applying a priori fixed discovery thresholds such as 0.05 limit the ability of investigators to identify and publish weak effects even when evidence suggests...
6.
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, et al.
Nat Commun . 2022 Feb; 13(1):857. PMID: 35165274
This randomized, open-label, multi-center phase 2 study (NCT03116152) assessed sintilimab, a PD-1 inhibitor, versus chemotherapy in patients with esophageal squamous cell carcinoma after first-line chemotherapy. The primary endpoint was overall...
7.
Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer
Arai H, Xiao Y, Millstein J, Wang J, Battaglin F, Kawanishi N, et al.
Br J Cancer . 2021 Oct; 126(1):72-78. PMID: 34689170
Background: The TIMELESS-TIPIN complex protects the replication fork from replication stress induced by chemotherapeutic drugs. We hypothesised genetic polymorphisms of the TIMELESS-TIPIN complex may affect the response, progression-free survival (PFS),...
8.
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study
Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B, et al.
J Thorac Oncol . 2021 Aug; 16(12):2109-2120. PMID: 34358724
Introduction: Sintilimab plus chemotherapy significantly prolonged progression-free survival (PFS) compared with chemotherapy alone in nonsquamous NSCLC in the ORIENT-11 study. Updated overall survival (OS) and PFS data and corresponding biomarker...
9.
RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC
Arai H, Cao S, Battaglin F, Wang J, Kawanishi N, Tokunaga R, et al.
Mol Cancer Ther . 2021 Mar; 20(6):1153-1160. PMID: 33785650
RNA-binding proteins (RBPs) regulate many posttranscriptional cellular activities. Accumulating evidence suggests associations between RBPs with colonic tumorigenesis and chemosensitivity. We investigated the prognostic and predictive values of SNPs of genes...
10.
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer
Arai H, Xiao Y, Loupakis F, Kawanishi N, Wang J, Battaglin F, et al.
J Immunother Cancer . 2020 Nov; 8(2). PMID: 33172883
Background: Immunogenic cell death (ICD) is a tumor cell death involving both innate and adaptive immune responses. Given published findings that oxaliplatin, but not irinotecan, drives ICD, we investigated whether...